Dmitry Gil

Dmitry Gil is a Principal Scientist at Amgen, where they focus on process development and drug product technology for oncolytic virus therapies. Prior to this role, they served as a Process Development Scientist at Amgen and worked as a Formulation and CMC Scientist II at Aviceda Therapeutics, where they established a nanoparticle formulation lab and developed strategic drug delivery systems. Dmitry completed a postdoctoral fellowship at Harvard Medical School and Massachusetts General Hospital, specializing in drug delivery systems and in-vitro characterization of novel materials. They earned their PhD in Bioengineering from Clemson University and hold a Master's degree in Chemistry from Lomonosov Moscow State University.